European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 felv-envelope antigen - inactivated viral vaccines, feline leukaemia virus, immunologicals for felidae, - cats - active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Israel - English - Ministry of Health

gilead sciences israel ltd - tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - viread is indicated for the treatment of :1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv. 2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease

Israel - English - Ministry of Health

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 2513.6 microgram (equivalent: fentanyl, qty 1600 microgram) - lozenge with integral application - excipient ingredients: citric acid; starch sodium octenyl succinate; dextrates; dibasic sodium phosphate; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 1885.2 microgram (equivalent: fentanyl, qty 1200 microgram) - lozenge with integral application - excipient ingredients: starch sodium octenyl succinate; dibasic sodium phosphate; dextrates; citric acid; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 1256.8 microgram (equivalent: fentanyl, qty 800 microgram) - lozenge with integral application - excipient ingredients: citric acid; dibasic sodium phosphate; starch sodium octenyl succinate; dextrates; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 942.6 microgram (equivalent: fentanyl, qty 600 microgram) - lozenge with integral application - excipient ingredients: starch sodium octenyl succinate; dextrates; magnesium stearate; dibasic sodium phosphate; citric acid; shellac; brilliant blue fcf; maize starch; sucrose; flavour - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 628.4 microgram (equivalent: fentanyl, qty 400 microgram) - lozenge with integral application - excipient ingredients: dibasic sodium phosphate; magnesium stearate; starch sodium octenyl succinate; dextrates; citric acid; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 314.2 microgram (equivalent: fentanyl, qty 200 microgram) - lozenge with integral application - excipient ingredients: dibasic sodium phosphate; citric acid; dextrates; starch sodium octenyl succinate; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.- avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. - avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. - avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.- avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.- avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).- avastin, in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.- avastin ( bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents - avastin ( bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix.- bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. - bevacizumab, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.